|
|
Volumn , Issue , 2009, Pages 587-589
|
|
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
DEXAMETHASONE;
DRUG DERIVATIVE;
IMMUNOLOGIC FACTOR;
LENALIDOMIDE;
PYRAZINE DERIVATIVE;
THALIDOMIDE;
CASE REPORT;
CLINICAL TRIAL;
EVIDENCE BASED MEDICINE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
MALE;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
MULTIPLE MYELOMA;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
REVIEW;
STATISTICS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
CLINICAL TRIALS AS TOPIC;
COMBINED MODALITY THERAPY;
DEXAMETHASONE;
EVIDENCE-BASED MEDICINE;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
IMMUNOLOGIC FACTORS;
INTERFERON-ALPHA;
MALE;
MIDDLE AGED;
MULTIPLE MYELOMA;
PRACTICE GUIDELINES AS TOPIC;
PYRAZINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REMISSION INDUCTION;
THALIDOMIDE;
|
|
EID: 77949437592
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation-2009.1.587 Document Type: Review |
|
Times cited : (13)
|
|
References (14)
|
